Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands-Reference-Cited by-同舟云学术

Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands

Published:2010-03-24 Issue:2 Volume:210 Page:161-168
ISSN:0033-3158
Container-title:Psychopharmacology
language:en
Short-container-title:Psychopharmacology

Author:

Ansonoff Michael A.,Portoghese Philip S.,Pintar John E.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s00213-010-1826-7.pdf

Reference33 articles.

1. Ansonoff MA, Zhang J, Czyzyk T, Rothman RB, Stewart J, Xu H, Zjwiony J, Siebert DJ, Yang F, Roth BL, Pintar JE (2006) Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice. J Pharmacol Exp Ther 318:641–648

2. Ansonoff MA, Wen T, Pintar JE (2010) Kappa2 opioid receptor subtype binding requires the presence of the DOR-1 gene. Front Biosci (Schol Ed) 2:772–780

3. Ballet S, Pietsch M, Abell AD (2008) Multiple ligands in opioid research. Protein Pept Lett 15:668–682

4. Bhushan RG, Sharma SK, Xie Z, Daniels DJ, Portoghese PS (2004) A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. J Med Chem 47:2969–2972

5. Daniels DJ, Kulkarni A, Xie Z, Bhushan RG, Portoghese PS (2005) A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes. J Med Chem 48:1713–1716

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Les hétéromères impliquant le récepteur opioïde δ : des cibles potentielles pour soulager la douleur chronique ?;Douleur et Analgésie;2022-09

2. Opioid Ligands Addressing Unconventional Binding Sites and More Than One Opioid Receptor Subtype;ChemMedChem;2022-05-31

3. An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects;Pharmacological Research;2022-03

4. Therapeutic potential of opioid receptor heteromers in chronic pain and associated comorbidities;British Journal of Pharmacology;2022-01-21

5. Itching-like behavior: A common effect of the kappa opioid receptor antagonist 5′-guanidinonaltrindole and the biased kappa opioid receptor agonist 6′-guanidinonaltrindole in mice;Medicine in Drug Discovery;2021-09